BartynskiWSBoardmanJFZeiglerZRShadduckRKListerJ. Posterior reversible encephalopathy syndrome in infection, sepsis, and shock. Am J Neuroradiol2006; 27: 2179–2190.
2.
LaiCCChenWSChangYS. Clinical features and outcomes of posterior reversible encephalopathy syndrome in patients with systemic lupus erythematosus. Arthritis Care Res2013; 65: 1766–1774.
3.
ShaharirSSRemliRMarwanAASaidMSKongNC. Posterior reversible encephalopathy syndrome in systemic lupus erythematosus: pooled analysis of the literature reviews and report of six new cases. Lupus2013; 22: 492–496.
SiddiqiAI. Rituximab as a possible cause of posterior reversible encephalopathy syndrome. Australas Med J2011; 4: 513–515.
6.
Ánchez-CarteyronAAlarciaRAraJRMartínJ. Posterior reversible encephalopathy syndrome after rituximab infusion in neuromyelitis optica. Neurology2010; 74: 1471–1473.
7.
MavraganiCPVlachoyiannopoulosPGKosmasNBoletisITzioufasAGVoulgarelisM. A case of reversible posterior leucoencephalopathy syndrome after rituximab infusion. Rheumatology2004; 43: 1450–1451.
8.
SaitoKNawataMNakayamadaSTokunagaMTsukadaJTanakaY. Successful treatment with anti-CD20 monoclonal antibody (rituximab) of life-threatening refractory systemic lupus erythematosus with renal and central nervous system involvement. Lupus2003; 12: 798–800.
9.
LeandroMJEdwardsJCCambridgeGEhrensteinMRIsenbergDA. An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum2002; 46: 2673–2677.
